Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma

Noorduyn, Stephen G.; Johnston, Karissa; Osenenko, Kathy M; Sriskandarajah, Niroshan; Gendron, Alain; Mbuagbaw, Lawrence

doi:10.1183/23120541.00465-2021

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, since treatment decision-making is based on different factors, including disease characteristics, effectiveness, patient preference, adherence, and socioeconomic status, real-world studies can offer the opportunity to investigate factors related to treatment initiation, dose adjustment or discontinuation and to examine switching patterns. Biological treatment discontinuation or switch is frequent in patients with SA, and RWD may help to understand patient factors or clinical outcomes associated with the treatment changes [98][99][100][101][102]. Some patients who did not respond to one biological agent may achieve a significant clinical improvement with other biologics [103].…”

Section: Opportunities For Real-world Studies In Severe Asthmamentioning

confidence: 99%

Roles of real-world evidence in severe asthma treatment: challenges and opportunities

Lee

Park

et al. 2022

ERJ Open Res

View full text Add to dashboard Cite

Recent advances in asthma research have led to the development of novel biologics that hinder the pathologic actions of key molecules in severe asthma (SA). Traditional randomised controlled studies (RCTs), the gold standard for evaluating the efficacy and safety of medical interventions with excellent internal validity, have proven the clinical benefits and favourable safety profiles of type 2-biologics in SA. However, RCTs are not always ideal because of shortcomings such as limited external validity and practical issues in the management of SA that could not be solved through strictly designed clinical trials. Thus, the applicability of their findings may be questioned for asthmatic patients because treatment adherence is frequently poor in the real world. Real-world evidence (RWE) includes a wide range of real-world data (RWD) collected from multiple sources in clinical practice, such as electronic medical records, healthcare insurance claims, and retrospective or prospective patient registries. It may help clinicians make decisions about the management of patients with SA. RWE is also gaining attention to address clinical questions not answered by traditional RCTs. Since there are various types of RWD with different possibilities and limitations, and thus it is important to decide which type of RWD could be “fit for purpose” to address a specific question. This narrative review is to discuss the challenges and opportunities of RWD for evaluating the effectiveness and clinical outcomes of biological treatments for SA.

show abstract

Section: Opportunities For Real-world Studies In Severe Asthmamentioning

confidence: 99%

Roles of real-world evidence in severe asthma treatment: challenges and opportunities

Lee

Park

et al. 2022

ERJ Open Res

View full text Add to dashboard Cite

show abstract

Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study

Faverio

Compagnoni

Ronco

et al. 2022

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

Defining response to therapy with biologics in severe asthma: from global evaluation to super response and remission

Papaioannou

Fouka

Bartziokas

et al. 2023

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma

Abstract: Within one year, 15% of Canadian patients with severe asthma discontinue benralizumab. The reasons for discontinuation are not yet characterized.

Cited by 3 publications

References 4 publications

Roles of real-world evidence in severe asthma treatment: challenges and opportunities

Roles of real-world evidence in severe asthma treatment: challenges and opportunities

Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study

Defining response to therapy with biologics in severe asthma: from global evaluation to super response and remission

Contact Info

Product

Resources

About